中央周围肝细胞染色质重塑经CYP450活性调控MASH
本研究在小鼠MASLD/MASH模型中探究Lgr5+肝细胞SWI/SNF亚基DPF2的作用,发现Dpf2缺失增加Cyp2启动子染色质可及性、驱动CYP2表达和atRA过度分解,降低肝脏AMPK磷酸化并加重MASLD;补充atRA可恢复AMPK活性并改善病情。
要点
- Lgr5+肝细胞Dpf2缺失破坏肝脏代谢稳态,导致显著脂质蓄积和辐射诱导肝损伤。
- DPF2缺失通过增加Cyp2启动子染色质可及性和组蛋白激活标记驱动CYP2表达。
- CYP2过度表达加速atRA分解,降低全肝AMPK磷酸化;补充atRA可 rescue AMPK并改善MASLD。
核心结论
- Lgr5+肝细胞中的DPF2经CYP2-atRA-AMPK轴调控肝脏代谢,是MASLD/MASH的潜在治疗靶点。
研究设计与样本
- 使用转基因C57BL/6J小鼠,以果糖-棕榈酸-胆固醇饮食或胆碱缺乏氨基酸 defined 高脂饮食诱导MASLD/MASH。
- 采用单细胞RNA测序、空间转录组、ATAC测序、CUT&Tag和CUT&RUN分析Lgr5+肝细胞中Cyp2基因的表观遗传和转录调控。
- 功能干预包括药理学全反式维甲酸(atRA)补充、CYP2抑制以及经腺相关病毒或流体动力学尾静脉注射的基因递送。
主要发现
- Lgr5+肝细胞中Dpf2缺失破坏肝脏代谢稳态,导致显著肝脏脂质蓄积和辐射诱导肝损伤(RILD)。
- DPF2缺失增加Cyp2启动子染色质可及性和组蛋白激活标记,驱动CYP2酶表达和atRA过度分解。
- atRA减少降低全肝AMPK磷酸化;恢复atRA可 rescue AMPK活性并改善MASLD严重程度。
临床怎么用
- 靶向染色质调控因子或维甲酸代谢通路可能为MASLD/MASH提供有效且安全的治疗获益。
- 系统性atRA给药可在全肝水平提供保护或预防作用。
- 肝脏全基因组遗传操作或批量组学分析可能掩盖局限于空间限制性细胞群体的关键致病机制。
局限性
- 临床转化需在更大规模人类队列和精心设计的患者研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lgr5+ hepatocytes constitute a specialized lineage central to nutrient and xenobiotic metabolism. In metabolic liver diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH), lipid accumulation occurs throughout the liver; however, zone-specific hepatocyte responses to metabolic stress remain poorly understood. Here, we investigated the role of the SWI/SNF subunit DPF2 in Lgr5+ hepatocytes and its contribution to hepatic metabolic homeostasis and radiation induced liver damage (RILD). METHODS: Transgenic C57BL/6J mice were fed fructose-palmitate-cholesterol or choline-deficient amino acid-defined and high fat diets under pathogen-free conditions to induce MASLD/MASH. Multi-modal analyses - including single-cell RNA sequencing, spatial transcriptomics, ATAC sequencing, CUT&Tag, and CUT&RUN - were used to define the epigenetic and transcriptional regulation of cytochrome P450 family 2 subfamily (Cyp2) genes in Lgr5+ hepatocytes. Functional interventions included pharmacological all-trans retinoic acid (atRA) supplementation, CYP2 inhibition, and gene delivery via adeno-associated viruses or hydrodynamic tail vein injection. RESULTS: Dpf2 deletion in Lgr5+ hepatocytes disrupted liver metabolic homeostasis, resulting in marked hepatic lipid accumulation and RILD. DPF2 loss increased chromatin accessibility and histone activation marks at Cyp2 promoters, driving CYP2 enzyme expression and excessive atRA catabolism. The resulting reduction in atRA decreased AMPK phosphorylation throughout the liver. Restoration of atRA rescued AMPK activity and ameliorated MASLD severity, highlighting a metabolite-mediated, non-cell-autonomous mechanism linking a small hepatocyte subset to whole-liver metabolic regulation. CONCLUSIONS: DPF2 in Lgr5+ hepatocytes is a critical regulator of hepatic metabolism, acting via the CYP2-atRA-AMPK axis. These findings reveal the mechanistic basis for zone-specific metabolic control in the liver and identify atRA homeostasis as a potential therapeutic target for MASLD and MASH. IMPACT AND IMPLICATIONS: This study dissects chromatin regulation across spatially distinct hepatocyte populations and demonstrates that DPF2 activity within a rare Lgr5+ hepatocyte subset is sufficient to drive metabolic reprogramming and MASLD progression. These findings have important implications for both liver research and clinical practice, highlighting how liver-wide genetic manipulations or bulk omics analyses may obscure key disease-driving mechanisms confined to spatially restricted cell populations. From a translational perspective, our data suggest that targeting chromatin regulators or retinoid metabolic pathways may provide effective and safe therapeutic benefit; notably, systemic atRA administration can still confer robust protection or prevention at the whole-liver level. Although supported by rigorous mouse genetics, high-resolution transcriptomics, and validation in human liver tissues, clinical translation will require confirmation in larger human cohorts and carefully designed patient studies.
引用
- Zhang Z, Lu S, Shu Y, et al. Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity. J Hepatol. 2026. PMID: 41935542. doi:10.1016/j.jhep.2026.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。